1. Scrip
  2. >>Conferences

DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications

Gastric, Lung And Colorectal Data Promising

 
• By Alexandra Shimmings

Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue. 

Digital illustration of lung cancer cells in color background
• Source: Shutterstock

New Phase II data for Daiichi Sankyo Co. Ltd./AstraZeneca PLC’s HER2-directed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) presented at ASCO reinforce its potential in three more tumor types where HER2 can play a role – gastric, lung and colorectal.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences